Table 1 Characteristics of 928 Swiss childhood cancer survivors invited to home collection of germline DNA, stratified by participation status
From: Predictors for participation in DNA self-sampling of childhood cancer survivors in Switzerland
| Â | Participation | Univariable logistic regression | Multivariable logistic regression | ||||
|---|---|---|---|---|---|---|---|
Characteristic | Total (n; %)a | Yes (n; %)a | No (n; %)a | OR (95%-CI) | p-value | OR (95%-CI) | p-value |
Sex | |||||||
Female | 426 (46) | 209 (45) | 217 (47) | Ref. | Â | Ref. | Â |
Male | 502 (54) | 254 (55) | 248 (53) | 1.06 (0.82 - 1.38) | 0.64 | 1.09 (0.83-1.42) | 0.53 |
Nationality | |||||||
Swiss | 710 (76) | 377 (81) | 333 (72) | Ref. | Â | Ref. | Â |
Foreign | 218 (24) | 86 (19) | 132 (28) | 0.58 (0.42-0.78) | < 0.001 | 0.53 (0.38-0.73) | < 0.001 |
Correspondence language | |||||||
German | 633 (68) | 308 (67) | 325 (70) | Ref. | Â | Ref. | Â |
French and Italian | 295 (32) | 155 (33) | 140 (30) | 1.17 (0.89-1.54) | 0.27 | 1.31 (0.98-1.75) | 0.07 |
Age at first neoplasm diagnosis | |||||||
Median (IQR; years) | 8.7 (3.0-13.4) | 8.7 (3.0-13.4) | 8.6 (3.6-13.3) | Â | Â | Â | Â |
0-4 years | 311 (33) | 166 (36) | 145 (31) | 1.14 (0.83 – 1.57) | 0.35 | 1.08 (0.75-1.56) | 0.4 |
5-9 years | 212 (23) | 97 (21) | 115 (25) | 0.84 (0.59 - 1.20) |  | 0.79 (0.54-1.14) |  |
10-14 years | 287 (31) | 144 (31) | 143 (31) | Ref. |  | Ref. |  |
15-20 years | 118 (13) | 56 (12) | 62 (13) | 0.90 (0.58 - 1.38) |  | 0.95 (0.61-1.48) |  |
Year of diagnosis | |||||||
1976-1985 | 110 (12) | 54 (12) | 56 (12) | 0.84 (0.55 - 1.30) | 0.02 | ‡ |  |
1986-1995 | 193 (21) | 78 (17) | 115 (25) | 0.59 (0.41 - 0.85) |  | ‡ |  |
1996-2005 | 312 (33) | 164 (35) | 148 (32) | 0.97 (0.71 - 1.33) |  | ‡ |  |
2006-2016 | 313 (34) | 167 (36) | 146 (31) | Ref. |  | ‡ |  |
Diagnostic group of first primary neoplasm (ICCC-3) | |||||||
Leukaemias, myeloproliferative and myelodysplastic diseases | 35 (4) | 14 (3) | 21 (5) | 0.77 (0.37-1.58) | 0.38 | Â | Â |
Lymphomas | 190 (20) | 95 (21) | 95 (20) | 1.15 (0.79-1.68) | Â | Â | Â |
CNS tumours and miscellaneous intracranial and intraspinal neoplasms | 256 (28) | 119 (26) | 137 (29) | Ref. | Â | Â | Â |
Neuroblastoma and other peripheral nervous cell tumours | 78 (8) | 45 (10) | 33 (7) | 1.57 (0.94-2.62) | Â | Â | Â |
Retinoblastoma | 44 (5) | 18 (4) | 26 (6) | 0.8 (0.42-1.53) | Â | Â | Â |
Renal tumours | 33 (4) | 20 (4) | 13 (3) | 1.77 (0.85-3.71) | Â | Â | Â |
Hepatic tumours | 24 (2) | 15 (3) | 9 (2) | 1.92 (0.81-4.54) | Â | Â | Â |
Malignant bone tumours | 100 (11) | 56 (12) | 44 (9) | 1.47 (0.92-2.33) | Â | Â | Â |
Soft tissue and other extraosseous sarcomas | 94 (10) | 48 (10) | 46 (10) | 1.2 (0.75-1.93) | Â | Â | Â |
Germ cell tumours, trophoblastic tumours, and neoplasms of gonads | 64 (7) | 29 (6) | 35 (8) | 0.95 (0.55-1.65) | Â | Â | Â |
Other malignant epithelial neoplasms and malignant melanomas | 6 (< 1) | 2 (< 1) | 4 (< 1) | 0.58 (0.1-3.2) |  |  |  |
Langerhans cell histiocytosis | 4 (< 1) | 2 (< 1) | 2 (< 1) | 1.15 (0.16-8.3) |  |  |  |
Chemotherapy | |||||||
No | 61 (7) | 25 (5) | 36 (8) | Ref. | Â | Â | Â |
Yes | 867 (93) | 438 (95) | 429 (92) | 1.47 (0.87-2.49) | 0.15 | Â | Â |
- With platinum agents | 491 (53) | 259 (56) | 232 (50) | 1.27 (0.98-1.64) | 0.07 | Â | Â |
Radiotherapy | |||||||
No | 319 (34) | 160 (35) | 159 (34) | Ref. | Â | Â | Â |
Yes | 609 (66) | 303 (65) | 306 (66) | 0.98 (0.75-1.29) | 0.91 | Â | Â |
- With head radiotherapy (≥30 Gy) | 343 (37) | 166 (36) | 177 (38) | 0.91 (0.70-1.19) | 0.49 |  |  |
- With chest radiotherapy | 328 (35) | 156 (34) | 172 (37) | 0.87 (0.66-1.33) | 0.29 | Â | Â |
Haematopoietic stem cell transplantation | |||||||
No | 864 (93) | 428 (92) | 436 (94) | Ref. | Â | Â | Â |
Yes | 64 (7) | 35 (8) | 29 (6) | 1.23 (0.74-2.05) | 0.43 | Â | Â |
Relapse of first neoplasm | |||||||
No | 738 (80) | 368 (79) | 370 (80) | Ref. | Â | Â | Â |
Yes | 190 (20) | 95 (21) | 95 (20) | 1.01 (0.73-1.38) | 0.97 | Â | Â |
Cancer predisposition syndrome | |||||||
No | 879 (95) | 442 (95) | 437 (94) | Ref. | Â | Ref. | Â |
Yes | 49 (5) | 21 (5) | 28 (6) | 0.74 (0.42-1.33) | 0.31 | 0.54 (0.29-1.0) | 0.05 |
Second primary neoplasm | |||||||
No | 889 (96) | 438 (95) | 451 (97) | Ref. | Â | Ref. | Â |
Yes | 39 (4) | 25 (5) | 14 (3) | 1.84 (0.94-3.58) | 0.07 | 1.92 (0.97-3.82) | 0.06 |
Age at study invitation | |||||||
Median (IQR; years) | 26.5 (18.8-36.5) | 25.1 (18.3-35.2) | 27.7 (19.5-37.3) | Â | Â | Â | Â |
< 10 years | 50 (6) | 23 (5) | 27 (6) | 0.72 (0.4-1.32) | 0.005 | 0.75 (0.39-1.43) | 0.002 |
10-19 years | 215 (23) | 121 (26) | 94 (20) | 1.09 (0.77-1.56) |  | 1.17 (0.81-1.70) |  |
20-29 years | 296 (32) | 160 (35) | 136 (29) | Ref. |  | Ref. |  |
30-39 years | 198 (21) | 78 (17) | 120 (26) | 0.55 (0.38-0.8) |  | 0.54 (0.38-0.79) |  |
40 or more years | 169 (18) | 81 (17) | 88 (19) | 0.78 (0.54-1.14) | Â | 0.72 (0.48-1.07) | Â |